CD39/ENTPD1 Antibody (2991A) [Dylight 594]
Novus Biologicals, part of Bio-Techne | Catalog # FAB11582M
Recombinant Monoclonal Antibody.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 2991A
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Chinese Hamster Ovary cell line, CHO-derived human CD39/ENTPD1
Thr38-Val478
Accession # P49961
Thr38-Val478
Accession # P49961
Specificity
Detects recombinant human CD39 protein in Direct ELISA.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for CD39/ENTPD1 Antibody (2991A) [Dylight 594]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD39/ENTPD1
Long Name
Ecto-Nucleoside Triphosphate Diphosphohydrolase 1
Alternate Names
ADPase, ATP-diphosphatase, CD39, ENTPD1, NTPD1
Additional CD39/ENTPD1 Products
Product Documents for CD39/ENTPD1 Antibody (2991A) [Dylight 594]
Product Specific Notices for CD39/ENTPD1 Antibody (2991A) [Dylight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...